CL AT 313 - Charleston Laboratories

Drug Profile

CL AT 313 - Charleston Laboratories

Alternative Names: CL-AT-313

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Charleston Laboratories
  • Class Antitussives; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Common cold; Cough; Respiratory hypersensitivity

Most Recent Events

  • 05 Feb 2016 Phase-I clinical trials in Common cold in USA (PO)
  • 05 Feb 2016 Phase-I clinical trials in Cough in USA (PO)
  • 05 Feb 2016 Phase-I clinical trials in Respiratory hypersensitivity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top